The Lancet publishes Capricor's phase 3 DMD therapy trial results
Go back to The Lancet publishes Capricor's phase 3 DMD therapy trial results| Capricor Therapeutics, Inc. (NASDAQ: CAPR) | Delayed: 9.08 -0.34 (3.61%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $9.42 | 52 Week High | $5.40 | |||
| Open | $9.30 | 52 Week Low | $1.88 | |||
| Day High | $9.36 | P/E | N/A | |||
| Day Low | $9.01 | EPS | $0.00 | |||
| Volume | 732,995 | |||||
